RS-2023-00218925

Candidate optimization of ARBM-101 as an innovative Wilson's disease drug

ARBORMED

ARBORMED

OTHERS | **Candidate**

Product Type	Small peptide
Indication	Wilson’s disease
Target	Abnormally accumulated Copper eliminates from the body, especially Liver tissue
MoA(Mechanism of Action)	• ARBM-101 has extraordinary copper binding affinity as a kind of chelator • Rapidly uptake to hepatocyte and excreted to the bile with copper as a copper-bound form • Due to the copper clearance from the liver, the damaged liver function is rescued/recovered 
Competitiveness	1. First-in-Class 2. Novel MoA : Different with the current SOC (Standard of Care), ARBM-101 can eliminates accumulated copper from the target tissue, liver 3. Normal physiology : Same as normal physiological copper excretion pathway, ARBM-101 excretes copper via feces whereas the current SOC excretes copper through urine 4. Maintenance dosing : It has been proved by in vivoexperiment that ARBM-101 can be administered with dosing resting period
Development Stage	Candidate
Route of Administration	IV

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund